Literature DB >> 24691943

Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.

Michael Vouche1, Ali Habib, Thomas J Ward, Edward Kim, Laura Kulik, Daniel Ganger, Mary Mulcahy, Talia Baker, Michael Abecassis, Kent T Sato, Juan-Carlos Caicedo, Jonathan Fryer, Ryan Hickey, Elias Hohlastos, Robert J Lewandowski, Riad Salem.   

Abstract

UNLABELLED: Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular carcinoma (HCC) <3 cm; there is interest in expanding the role of ablation to 3-5 cm. RFA is considered high-risk when the lesion is in close proximity to critical structures. Combining microcatheter technology and the localized emission properties of Y90, highly selective radioembolization is a possible alternative to RFA in such cases. We assessed the efficacy (response, radiology-pathology correlation, survival) of radiation segmentectomy in solitary HCC not amenable to RFA or resection. Patients with treatment-naïve, unresectable, solitary HCC ≤ 5 cm not amenable to RFA were included in this multicenter study. Administered dose, response rate, time-to-progression (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), radiology-pathology correlation and long-term survival were assessed. In all, 102 patients were included in this study. mRECIST complete response (CR), partial response (PR), and stable disease (SD) were 47/99 (47%), 39/99 (39%), and 12/99 (12%), respectively. Median time-to-disease-progression was 33.1 months. In all, 33/102 (32%) patients were transplanted with a median (interquartile range [IQR]) time-to-transplantation of 6.3 months (3.6-9.7). Pathology revealed 100% and 50-99% necrosis in 17/33 (52%) and 16/33 (48%), respectively. Median overall survival was 53.4 months. Univariate analysis demonstrated a survival benefit for Eastern Cooperative Oncology Group (ECOG) 0 patients. In the multivariate model, age <65, ECOG 0, and Child-Pugh A were characteristics associated with longer survival.
CONCLUSION: Radiation segmentectomy is an effective technique with a favorable risk profile and radiology-pathology outcomes for solitary HCC ≤ 5 cm. This approach may allow for treatment of HCC in difficult locations. Since RFA and resection are not options given tumor location, there appears to be a strong rationale for this technique as second choice.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24691943     DOI: 10.1002/hep.27057

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  64 in total

Review 1.  Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.

Authors:  Samdeep K Mouli; Laura W Goff
Journal:  Curr Treat Options Oncol       Date:  2017-10-27

Review 2.  Transarterial approaches to primary and secondary hepatic malignancies.

Authors:  Ali Habib; Kush Desai; Ryan Hickey; Bartley Thornburg; Robert Lewandowski; Riad Salem
Journal:  Nat Rev Clin Oncol       Date:  2015-05-19       Impact factor: 66.675

Review 3.  Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.

Authors:  Julien Edeline; Marine Gilabert; Etienne Garin; Eveline Boucher; Jean-Luc Raoul
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

4.  Yttrium-90 radioembolization for hepatocellular carcinoma in hepatitis B: commentary on a 103-patient Asian cohort.

Authors:  Laura Kulik; Riad Salem
Journal:  Hepatol Int       Date:  2014-07-23       Impact factor: 6.047

5.  Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.

Authors:  Riad Salem; Siddharth A Padia; Marnix Lam; Jon Bell; Carlo Chiesa; Kirk Fowers; Bonnie Hamilton; Joseph Herman; S Cheenu Kappadath; Thomas Leung; Lorraine Portelance; Daniel Sze; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-16       Impact factor: 9.236

Review 6.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 7.  Yttrium-90 Radiation Segmentectomy.

Authors:  Guy E Johnson; Siddharth A Padia
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

Review 8.  Frontiers of therapy for hepatocellular carcinoma.

Authors:  Michael Heller; Neehar D Parikh; Nicholas Fidelman; Dawn Owen
Journal:  Abdom Radiol (NY)       Date:  2021-04-10

Review 9.  Radioembolization of Colorectal Liver Metastases: Indications, Technique, and Outcomes.

Authors:  F Edward Boas; Lisa Bodei; Constantinos T Sofocleous
Journal:  J Nucl Med       Date:  2017-09       Impact factor: 10.057

10.  Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.

Authors:  Riad Salem; Andrew C Gordon; Samdeep Mouli; Ryan Hickey; Joseph Kallini; Ahmed Gabr; Mary F Mulcahy; Talia Baker; Michael Abecassis; Frank H Miller; Vahid Yaghmai; Kent Sato; Kush Desai; Bartley Thornburg; Al B Benson; Alfred Rademaker; Daniel Ganger; Laura Kulik; Robert J Lewandowski
Journal:  Gastroenterology       Date:  2016-08-27       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.